Soluble recombinant trail

Caki cells were obtained from the American Type Culture Collection (ATCC: Rockville, MD, USA). The culture medium used for all experiments consisted of Dulbecco's modified Eagle Medium supplemented with 10% fetal bovine serum, 20 mM HEPES buffer, and 100 μg/mL gentamicin. The anti-Bcl-2, -procaspase-3, -PARP, and -actin antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The anti-c-FLIP antibody was purchased from ALEXIS Corporation (San Diego, CA, USA). Soluble recombinant TRAIL was purchased from R&D Systems (Minneapolis, MN, USA). TG and Dox were obtained from Sigma Chemical Co (Saint Louis, MO). Anti-DR5 was purchased from KOMA Biotech Inc. (Seoul, Korea).

Caki-1 cells were obtained from the American Type Culture Collection (Rockville, MD, USA). Caki-1 cells cell lines were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Welgene, Daegu, Korea) supplemented with 20 mM HEPES buffer, and 100 μg/mL gentamicin. The antibody against PARP was from Cell Signaling Technology, Inc. (Boston, MA, USA). Antibodies against caspase-3, -TBCK, and -actin antibodies were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). Cisplatin was obtained from Sigma Chemical Co. (St. Louis, MO, USA). Soluble recombinant TRAIL was purchased from R&D Systems (Minneapolis, MN, USA).